Bayer AG
BET:BAYER
Bayer AG
Bayer AG, a German multinational behemoth, traces its roots back to 1863 in Barmen, when Friedrich Bayer and Johann Friedrich Weskott began their enterprise as a dye-making factory. Fast forward to the present day, and Bayer has evolved into a global powerhouse, seamlessly weaving through pharmaceuticals, consumer health, and agricultural science. At its core, Bayer’s business operations spin around its three main segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division is the jewel in Bayer’s crown, focusing on prescription medicines across various therapeutic areas such as oncology, cardiology, and gynecology, allowing Bayer to cater to the world's increasing demand for healthcare solutions, which not only drive patient outcomes but also account for a significant chunk of revenue.
Not to be overshadowed, Bayer’s Crop Science division plays a pivotal role, emphasizing its strong commitment to sustainable agriculture. Here, the company develops seeds, traits, and crop protection products that appeal to farmers seeking to enhance yield and manage crop threats. Meanwhile, the Consumer Health division targets over-the-counter products, covering a range of everyday health issues, resonating with consumers seeking self-care solutions. Bayer’s ability to seamlessly integrate its scientific prowess into real-world applications enables the company to extract value across these sectors, creating an intricate mosaic of interdependent streams of revenue and continually reinforcing its stature as a leader in life sciences.
Bayer AG, a German multinational behemoth, traces its roots back to 1863 in Barmen, when Friedrich Bayer and Johann Friedrich Weskott began their enterprise as a dye-making factory. Fast forward to the present day, and Bayer has evolved into a global powerhouse, seamlessly weaving through pharmaceuticals, consumer health, and agricultural science. At its core, Bayer’s business operations spin around its three main segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division is the jewel in Bayer’s crown, focusing on prescription medicines across various therapeutic areas such as oncology, cardiology, and gynecology, allowing Bayer to cater to the world's increasing demand for healthcare solutions, which not only drive patient outcomes but also account for a significant chunk of revenue.
Not to be overshadowed, Bayer’s Crop Science division plays a pivotal role, emphasizing its strong commitment to sustainable agriculture. Here, the company develops seeds, traits, and crop protection products that appeal to farmers seeking to enhance yield and manage crop threats. Meanwhile, the Consumer Health division targets over-the-counter products, covering a range of everyday health issues, resonating with consumers seeking self-care solutions. Bayer’s ability to seamlessly integrate its scientific prowess into real-world applications enables the company to extract value across these sectors, creating an intricate mosaic of interdependent streams of revenue and continually reinforcing its stature as a leader in life sciences.
Sales & earnings: Group sales were EUR 45.5 billion and core earnings per share were EUR 4.91 in 2025, with free cash flow of EUR 2.1 billion — all within the raised guidance corridor.
Litigation: Bayer recorded EUR 7.5 billion of litigation-related special items in 2025 and says litigation provisions and liabilities total EUR 11.8 billion; the company expects about EUR 5 billion of litigation‑related payouts in 2026 and is managing a settlement/class process alongside a pending U.S. Supreme Court decision.
2026 outlook: Management expects 2026 net sales of EUR 45–47 billion, EBITDA before special items of EUR 9.6–10.1 billion and core EPS of EUR 4.30–4.80; free cash flow is forecast negative at minus EUR 1.5 to minus EUR 2.5 billion, driving net financial debt to roughly EUR 32–33 billion.
Pharma launches driving growth: Nubeqa and Kerendia combined sales reached EUR 3.2 billion and are expected to grow strongly (management cites ~50% growth in 2026); new launches (Beyonttra, Lynkuet, Asundexian) are key to offset mature-product declines.
Crop Science progress and licensing: Crop Science reported resilient results (group growth ~1% currency/portfolio adjusted) and recognized licensing income, including EUR 300 million in Q4 '25 (corn) and about EUR 450 million expected to support Q1 '26 (soy); glyphosate sales are expected to fall 2%–6% in 2026 due to pricing pressures.
Consumer Health resilience: Consumer Health delivered EUR 5.8 billion in sales in 2025 (roughly flat vs prior year) and is executing its Road to Billion strategy; 2026 sales guidance is 0%–4% with a margin target of 22%–24%.
Operational transformation: Management highlighted a leaner organization, EUR 2 billion target for organizational savings, faster launches and improved cash conversion as priorities to sustain recovery.
FX & geopolitical risk: FX was a material headwind in 2025 (~EUR 1.7 billion to sales) and is expected to subtract about EUR 0.30 from core EPS in 2026; management is monitoring geopolitical volatility and tariff risks.
